TSPAN32 and Burkitt lymphoma: Future studies should focus on elucidating the precise molecular mechanisms through which TSPAN32 contributes to B cell development and BL pathogenesis, as well as the therapeutic potential of targeting TSPAN32 dysregulation in these types of lymphomas.